Cargando…

Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa

Vaccines for Pseudomonas aeruginosa have been of longstanding interest to immunologists, bacteriologists, and clinicians, due to the widespread prevalence of hospital-acquired infection. As P. aeruginosa becomes increasingly antibiotic resistant, there is a dire need for novel treatments and prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoggarth, Austin, Weaver, Andrew, Pu, Qinqin, Huang, Ting, Schettler, Jacob, Chen, Feng, Yuan, Xiefang, Wu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431001/
https://www.ncbi.nlm.nih.gov/pubmed/30936684
http://dx.doi.org/10.2147/DDDT.S189847
_version_ 1783405864109998080
author Hoggarth, Austin
Weaver, Andrew
Pu, Qinqin
Huang, Ting
Schettler, Jacob
Chen, Feng
Yuan, Xiefang
Wu, Min
author_facet Hoggarth, Austin
Weaver, Andrew
Pu, Qinqin
Huang, Ting
Schettler, Jacob
Chen, Feng
Yuan, Xiefang
Wu, Min
author_sort Hoggarth, Austin
collection PubMed
description Vaccines for Pseudomonas aeruginosa have been of longstanding interest to immunologists, bacteriologists, and clinicians, due to the widespread prevalence of hospital-acquired infection. As P. aeruginosa becomes increasingly antibiotic resistant, there is a dire need for novel treatments and preventive vaccines. Despite intense efforts, there currently remains no vaccine on the market to combat this dangerous pathogen. This article summarizes current and past vaccines under development that target various constituents of P. aeruginosa. Targeting lipopolysaccharides and O-antigens have shown some promise in preventing infection. Recombinant flagella and pili that target TLR5 have been utilized to combat P. aeruginosa by blocking its motility and adhesion. The type 3 secretion system components, such as needle-like structure PcrV or exotoxin PopB, are also potential vaccine targets. Outer membrane proteins including OprF and OprI are newer representatives of vaccine candidates. Live attenuated vaccines are a focal point in this review, and are also considered for novel vaccines. In addition, phage therapy is revived as an effective option for treating refractory infections after failure with antibiotic treatment. Many of the aforementioned vaccines act on a single target, thus lacking a broad range of protection. Recent studies have shown that mixtures of vaccines and combination approaches may significantly augment immunogenicity, thereby increasing their preventive and therapeutic potential.
format Online
Article
Text
id pubmed-6431001
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-64310012019-04-01 Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa Hoggarth, Austin Weaver, Andrew Pu, Qinqin Huang, Ting Schettler, Jacob Chen, Feng Yuan, Xiefang Wu, Min Drug Des Devel Ther Review Vaccines for Pseudomonas aeruginosa have been of longstanding interest to immunologists, bacteriologists, and clinicians, due to the widespread prevalence of hospital-acquired infection. As P. aeruginosa becomes increasingly antibiotic resistant, there is a dire need for novel treatments and preventive vaccines. Despite intense efforts, there currently remains no vaccine on the market to combat this dangerous pathogen. This article summarizes current and past vaccines under development that target various constituents of P. aeruginosa. Targeting lipopolysaccharides and O-antigens have shown some promise in preventing infection. Recombinant flagella and pili that target TLR5 have been utilized to combat P. aeruginosa by blocking its motility and adhesion. The type 3 secretion system components, such as needle-like structure PcrV or exotoxin PopB, are also potential vaccine targets. Outer membrane proteins including OprF and OprI are newer representatives of vaccine candidates. Live attenuated vaccines are a focal point in this review, and are also considered for novel vaccines. In addition, phage therapy is revived as an effective option for treating refractory infections after failure with antibiotic treatment. Many of the aforementioned vaccines act on a single target, thus lacking a broad range of protection. Recent studies have shown that mixtures of vaccines and combination approaches may significantly augment immunogenicity, thereby increasing their preventive and therapeutic potential. Dove Medical Press 2019-03-20 /pmc/articles/PMC6431001/ /pubmed/30936684 http://dx.doi.org/10.2147/DDDT.S189847 Text en © 2019 Hoggarth et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Hoggarth, Austin
Weaver, Andrew
Pu, Qinqin
Huang, Ting
Schettler, Jacob
Chen, Feng
Yuan, Xiefang
Wu, Min
Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa
title Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa
title_full Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa
title_fullStr Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa
title_full_unstemmed Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa
title_short Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa
title_sort mechanistic research holds promise for bacterial vaccines and phage therapies for pseudomonas aeruginosa
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431001/
https://www.ncbi.nlm.nih.gov/pubmed/30936684
http://dx.doi.org/10.2147/DDDT.S189847
work_keys_str_mv AT hoggarthaustin mechanisticresearchholdspromiseforbacterialvaccinesandphagetherapiesforpseudomonasaeruginosa
AT weaverandrew mechanisticresearchholdspromiseforbacterialvaccinesandphagetherapiesforpseudomonasaeruginosa
AT puqinqin mechanisticresearchholdspromiseforbacterialvaccinesandphagetherapiesforpseudomonasaeruginosa
AT huangting mechanisticresearchholdspromiseforbacterialvaccinesandphagetherapiesforpseudomonasaeruginosa
AT schettlerjacob mechanisticresearchholdspromiseforbacterialvaccinesandphagetherapiesforpseudomonasaeruginosa
AT chenfeng mechanisticresearchholdspromiseforbacterialvaccinesandphagetherapiesforpseudomonasaeruginosa
AT yuanxiefang mechanisticresearchholdspromiseforbacterialvaccinesandphagetherapiesforpseudomonasaeruginosa
AT wumin mechanisticresearchholdspromiseforbacterialvaccinesandphagetherapiesforpseudomonasaeruginosa